[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Ihtiyar E, Algin C, Isiksoy S, Ates E: Small cell carcinoma of rectum: a case report. World J Gastroenterol; 2005 May 28;11(20):3156-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of rectum: a case report.
  • We present a case of a 40-year-old woman with small-cell carcinoma (SCC) of the rectum.
  • She had profuse bleeding in rectum for 5 d.
  • By colonoscopy, polyps were determined in the rectum and biopsies were carried out.
  • Because of the profuse bleeding in rectum, she underwent low anterior resection.
  • After the diagnosis of SCC, she received intravenous chemotherapy with standard doses of siklofosfamid, adriamycin, and vepesid.
  • [MeSH-major] Carcinoma, Small Cell. Rectal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918209.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305859
  •  go-up   go-down


2. Ayadi L, Zribi J, Mziou TJ, Ellouz S, Khabir A, Bahri I, Turki H, Sellami-Boudawara T: [Scalp metastasis from small cell carcinoma of the rectum: an unusual case]. Tunis Med; 2009 May;87(5):354-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Scalp metastasis from small cell carcinoma of the rectum: an unusual case].
  • [Transliterated title] Métastase au niveau du cuir chevelu d'un carcinome a petites cellules du rectum: un cas inhabituel.
  • BACKGROUND: Cutaneous metastasis of rectal carcinoma is a rare event.
  • CASE REPORT: Our patient was a 63-year old male with a history of small cell carcinoma of the rectum who subsequently developed a single nodule of the scalp of 4cm.
  • Histopathological analysis revealed a small cell carcinoma infiltrating the dermis and subcutaneous tissue.
  • The patient underwent palliative chemotherapy but his disease continued to progress.
  • CONCLUSION: In contrast to the prior cases of scalp metastases reported in the literature, ours is the first documentation of such an occurrence from rectal small cell carcinoma.
  • The early diagnosis of skin metastases in these patients is very important because it can alter treatment.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Rectal Neoplasms / pathology. Scalp. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927770.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


3. Yang SW, Moon W: [A case of pseudomenbranous colitis after paclitaxel and carboplatin chemotherapy]. Korean J Gastroenterol; 2009 Nov;54(5):328-32
Hazardous Substances Data Bank. METRONIDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pseudomenbranous colitis after paclitaxel and carboplatin chemotherapy].
  • Antibiotics-associated pseudomembranous colitis is well documented and caused by abnormal overgrowth of toxin producing Clostridium difficile colonizing the large bowel of patients undergoing antibiotic therapy.
  • We experienced a 67 old-years male patient diagnosed of non-small cell lung carcinoma who complained of watery diarrhea and abdominal pain after treated with paclitaxel and carboplatin.
  • Sigmoidoscopic examination revealed diffusely scattered, whitish to yellowish pseudomembrane with background edematous hyperemic mucosa from sigmoid colon to rectum.
  • The symptoms improved after stopping chemotherapy and treatment with metronidazole.
  • In patients with persistent diarrhea and abdominal pain after receiving chemotherapy agents, although rare, pseudomembranous colitis should be considered as a differential diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / adverse effects. Enterocolitis, Pseudomembranous / diagnosis. Paclitaxel / adverse effects
  • [MeSH-minor] Aged. Anti-Infective Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Diagnosis, Differential. Humans. Lung Neoplasms / drug therapy. Male. Metronidazole / therapeutic use. Sigmoidoscopy. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934614.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 140QMO216E / Metronidazole; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Kuratate S, Inoue S, Chikakiyo M, Kaneda Y, Harino Y, Hirose T, Yagi T, Saitoh S, Sumitomo M, Fujino R, Satake N: Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case. J Med Invest; 2010 Aug;57(3-4):338-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case.
  • A 74-years old man was referred to our hospital for treatment of a rectal mass.
  • Biopsy yielded a diagnosis of adenoma.
  • CT examination showed tumor shadows of the rectum and the liver.
  • Pelvic MRI examination showed a 10.5×8×7 cm tumor with high signal intensity on the T2 weighted images in the rectum.
  • Rectosigmoidectomy with lymph node dissection was performed with the diagnosis of rectal cancer that metastasized to the liver.
  • Histological and immuno- histochemical features showed coexistent poorly-differentiated small cell neuroendocrine cell (NEC) carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma.
  • However the chemotherapy with FOLFOX and Bevacizumab was performed postoperatively, the patient died in cancer 3 months after surgery.
  • They would be evaluated, and effective multimodal therapy for NEC carcinomas should be established.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847536.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Kambayashi T, Ri M, Yanagihara K, Miyahara R, Bando T, Hasegawa S, Inui K, Wada H: [A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel]. Gan To Kagaku Ryoho; 2003 Jun;30(6):841-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel].
  • A 69-year-old man had undergone low anterior resection and a right lobe resection of the liver for rectum cancer and metastatic liver tumor at the age of 66 years.
  • A bronchoscopic tumor biopsy revealed pulmonary metastasis from the rectum cancer.
  • Bronchoscopic examination also identified an endobronchial squamous cell lung cancer, which almost completely obstructed the orifice of B1 and B2.
  • We concluded that the patient had squamous cell lung cancer with metastases in the mediastinal lymph nodes.
  • He was initially treated with weekly chemotherapy with carboplatin (AUC 1.25) and paclitaxel (70 mg/m2).
  • The endobronchial tumor was markedly reduced in size after 2 weeks of the chemotherapy.
  • Furthermore, after 6 weeks of the chemotherapy, the tumor had disappeared completely, and 11 days later, lower division segmentectomy and hilar and mediastinal lymph node dissection were performed.
  • The patient has continued to receive chemotherapy as an outpatient and has been well without recurrence of any metastases for over 16 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Humans. Lymphatic Metastasis. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852353.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 8
  •  go-up   go-down


6. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • Tumor hypoxia reduces the effectiveness of both radiation therapy and chemotherapy and is a well-known risk factor for tumor radioresistence.
  • Eleven patients also underwent clinical positron emission tomography with (18)F-fluorodeoxyglucose at the discretion of the treating clinician.
  • The primary tumor was imaged by positron emission tomography with (60)Cu-ATSM, and accumulation of the tracer was measured semiquantitatively by determining the tumor-to-muscle activity ratio.
  • Neoadjuvant chemoradiotherapy was then administered (within 2 weeks of (60)Cu-ATSM-positron emission tomography) and consisted of 45 Gy given in 25 fractions to the pelvis with continuous intravenous infusion of 5-fluorouracil (225 mg/m(2)/day).
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones
  • [MeSH-minor] Adult. Aged. Cell Hypoxia. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


7. Tokatli F, Koçak Z, Ozyilmaz F, Uygun K, Caloglu M, Uzal C: Small cell carcinoma of the rectum; report of a case. J BUON; 2002 Jan-Mar;7(1):75-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the rectum; report of a case.
  • Primary small cell undifferentiated carcinoma of the colon and rectum is a relatively rare tumour with an overall incidence of less than 1% among all colorectal cancers.
  • Despite the mean survival being around 6 months, long-term survival may be achieved in patients with localized disease treated with curative resection and adjuvant therapy.
  • We report on a patient with Dukes' C small cell carcinoma (SCC) of the rectum who underwent surgery followed by pelvic irradiation and chemotherapy and achieved long-term survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577266.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Doddi S, Singhal T, De Silva C, Smedley F, Sinha P, Leslie M: Small cell carcinoma of the anus: a case report. Cases J; 2009;2:9396

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the anus: a case report.
  • Small cell carcinoma of the anus is a very rare but aggressive tumour.
  • We present a case of a 60-year old lady with small cell carcinoma of the anus.
  • She had chemotherapy and radiotherapy but developed distant metastasis after completion of treatment.
  • Immunohistochemistry is required to make a diagnosis.
  • Chemotherapy remains the mainstay of treatment for small cell carcinoma of the anus with or without metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1068-76 [17614337.001]
  • [Cites] Histopathology. 2007 Jan;50(1):163-74 [17204029.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3156-8 [15918209.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Dec;5(12):692-3 [18852720.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Surg Today. 2002;32(1):72-4 [11871823.001]
  • [Cites] Surg Today. 1993;23(1):85-8 [8384908.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):635-42 [8026228.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • (PMID = 20076782.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806881
  •  go-up   go-down


9. Yuan ZY, Guan ZZ, Zhou ZM, Xia Y, Huang WZ, Yang XL: [Extrapulmonary small cell carcinoma in 52 patients]. Ai Zheng; 2006 Sep;25(9):1131-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapulmonary small cell carcinoma in 52 patients].
  • BACKGROUND & OBJECTIVE: The majority of small cell carcinoma occurs in the lung.
  • Extrapulmonary small cell carcinoma (ESCC) has been recognized as a clinicopathologic entity distinct from small cell carcinoma of the lung.
  • The study was to investigate the clinical characteristics, therapy, and prognosis of ESCC.
  • Of the 53 cases of ESCC, 33 (62.3%) were detected in the esophagus, 5 in the cervix, 4 in the larynx, 3 in the pharynx, 2 in the upper sinus, 2 in the rectum and sublingual gland, 1 in the thyroid gland, 1 in the pleura, and 1 in the liver.
  • Patients with ED mostly received platinum-based chemotherapy, for which the response rate was 69.2%.
  • Patients with LD were treated with a variety of therapeutic modalities: 7 were treated with surgery plus radiochemotherapy, 3 with surgery plus radiotherapy, 18 with surgery plus chemotherapy, 6 with radiotherapy plus chemotherapy, 4 with radiotherapy alone, and 2 with chemotherapy alone.
  • The median survival time (MST) was 20 months for all patients, and the 1-and 3-year survival rates were 41.3% and 31.4%.
  • Multimodality therapy has become increasingly used for the majority of patients with LD-ESCC.
  • Combination chemotherapy has been a major treatment for patients with ED-ESCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell. Esophageal Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adult. Aged. Cobalt Radioisotopes. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Particle Accelerators. Retrospective Studies. Survival Rate. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965656.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


10. Chalermchai T, Suwanrusme H, Chantranuwat P, Voravud N, Sriuranpong V: Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005. Asia Pac J Clin Oncol; 2010 Jun;6(2):111-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005.
  • OBJECTIVE: The aim of this study was to review cases of extra-pulmonary small cell carcinoma (EPSCC), including their clinical manifestations and treatment outcomes.
  • Nine patients underwent radical surgery alone, four received only radical radiation and two received only palliative chemotherapy.
  • Two patients received adjuvant radiation or chemotherapy following surgical resection and one received a combination of all three treatment modalities.
  • Three patients declined specific treatment and were treated with best supportive care.
  • EPSCC of pancreas demonstrated a favorable clinical outcome with treatment, whereas primary EPSCC of the liver, esophagus and rectum had an aggressive natural history and a poor response to treatment.
  • CONCLUSION: Our report suggests that EPSCC may have a different biology from that of pulmonary small cell carcinoma.
  • When detected at an early stage, EPSCC may have an excellent prognosis with treatment.
  • Additional studies involving more patients with EPSCC are warranted to further define the optimal roles of each treatment modality.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565423.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Number-of-references] 15
  •  go-up   go-down


11. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K: Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol; 2004 May;34(5):250-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small-cell carcinoma: a single-institution experience.
  • BACKGROUND: Extrapulmonary small-cell carcinoma (EPSCC) has been recognized as a clinicopathological entity distinct from small-cell carcinoma (SCC) of the lung.
  • This study aimed to review the clinical features, therapy and natural course of patients with EPSCC in Oriental single-institution series.
  • RESULTS: Twenty-four patients with EPSCC were identified and primary sites were various: uterine cervix in seven (29%), urinary bladder in five, colon or rectum in three, kidney in two and stomach, esophagus, pancreas, common bile duct, larynx, parotid gland, thymus in one each.
  • Patients with ED received mostly platinum-based chemotherapy, for which the response rate was 57%, but showed an aggressive natural history, with median overall survival (OS) of 9.2 months.
  • Patients with LD were treated with a variety of therapeutic modalities.
  • Regardless of the primary site or disease stage, EPSCC of sites other than cervix was usually a fatal disease with a discouraging outcome for various treatment modalities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Gastrointestinal Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome


12. Masuzawa T, Fujitani K, Hirao M, Kashiwazaki M, Ikenaga M, Mishima H, Nakamori S, Tsujinaka T, Takeda M: [A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1741-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11].
  • When a male patient(age: 63)came to our hospital to report his discomfort in swallowing on February 16, 2005, we observed that a tumor of the subcircular type 2 had invaded his descending aorta directly, which was equivalent to the range from tracheal bifurcation to esophagogastric junction.
  • At the same time, we found multiple metastases in lymph node which were from both cervixes to the range around the aorta abdominalis, and pleural effusion on both sides.
  • We diagnosed them as small cell type undifferentiated esophageal carcinoma(T4N4M1, Stage IVb)with esophagus lesion.
  • We started chemotherapy with irinotecan(CPT-11)and cisplatin(CDDP)in accordance with the guideline of the treatment for lung small cell carcinoma.
  • Five days after we began the chemotherapy, leukopenia(grade 4)and abrupt bloody diarrhea were observed.
  • Pathologic anatomy reported was necrosis of intestinal mucosa which ranged widely from his duodenum to rectum.
  • We reported this fatal case of small cell type undifferentiated carcinoma of the esophagus caused by treatment with CPT-11, which triggered abrupt diarrhea and bloody discharge.
  • [MeSH-major] Camptothecin / analogs & derivatives. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Diarrhea / complications. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Hemorrhage / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Cisplatin / adverse effects. Cisplatin / therapeutic use. Fatal Outcome. Humans. Male. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931579.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction.
  • We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome.
  • We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Small tumors of the anal margin were not included since they were treated by surgical excision only.
  • Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy.
  • All patients were scheduled for simultaneous chemotherapy with two cycles of 5-fluorouracil at a dose of 1000 mg/m (2)/day as 120 hours of continuous intravenous infusion on Days 1 to 5 and 29 to 33 and mitomycin C at 10 mg/m (2)/day on Days 1 and 29.
  • Median follow-up time was was 7.5 (range, 1-16) years.
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • However, patients with larger lesions of the perianal skin are at high risk for locoregional recurrence and possible treatment intensification in this subgroup seems desirable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Jahraus CD, Glisson SD, St Clair WH: Treatment of desmoplastic small round cell tumor with image-guided intensity modulated radiation therapy as a component of multimodality treatment. Tumori; 2005 May-Jun;91(3):253-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of desmoplastic small round cell tumor with image-guided intensity modulated radiation therapy as a component of multimodality treatment.
  • AIMS AND BACKGROUND: The authors report the case of a 31-year-old black male diagnosed with a pelvic desmoplastic small round-cell tumor who was treated with a unique radiotherapy approach incorporating intensity-modulated radiotherapy and daily ultrasound localization to ensure accurate tumor targeting.
  • Desmoplastic small round-cell tumor is a very rare tumor, most commonly presenting in the abdominopelvic regions of adolescents and young adults.
  • METHODS: The patient initially underwent biopsy of the mass and omentectomy for mesenteric implants followed by chemotherapy.
  • Chemotherapy resulted in tumor shrinkage and was followed by a second-look laparotomy.
  • Additional omental nodules were resected, but the primary tumor was adherent to the rectum and seminal vesicles.
  • The patient was subsequently started on further chemotherapy, which has maintained the disease in a stable state for several months.
  • CONCLUSIONS: Image-guided intensity-modulated radiotherapy is a feasible option in the treatment of pelvic desmoplastic small round-cell tumor.
  • Such therapy may permit escalation of conventional radiotherapy doses and could have a favorable impact on local control of disease.
  • Pending such confirmation, we continue to be of the impression that desmoplastic small round-cell tumor has an overall unfavorable prognosis, regardless of treatment modalities employed.
  • [MeSH-major] Abdominal Neoplasms / radiotherapy. Carcinoma, Small Cell / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dose Fractionation. Humans. Male. Radiotherapy / methods

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206650.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Spigel DR, Hainsworth JD, Greco FA: Neuroendocrine carcinoma of unknown primary site. Semin Oncol; 2009 Feb;36(1):52-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinoma of unknown primary site.
  • Most of these carcinomas probably arise from an occult/clinically undetectable primary site in one of several locations (bronchus, pancreas, stomach, colon, rectum and several other sites).
  • Patients with these tumors are a subset of unknown primary carcinoma with relatively favorable prognoses.
  • Targeted therapies may have a role in the treatment of low-grade tumors.
  • The high-grade or poorly differentiated carcinomas, including small cell and large cell neuroendocrine tumors, are rapidly growing and aggressive but responsive to platinum-based combination chemotherapy.
  • Poorly differentiated large cell neuroendocrine tumors, first reported in 1988, are usually not recognized by routine hematoxylin and eosin light microscopy but require immunohistochemical stains or electron microscopy for their diagnosis.
  • A review of cytotoxic chemotherapy for patients with high-grade neuroendocrine carcinomas, including a series of 99 patients, revealed an overall response rate of 70%, with a 20% complete response rate.
  • Tumor grade/differentiation currently is an important determinant of the management of these patients, and therapy in the future will be based on a more precise knowledge of the unique biology of these tumors.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179188.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


17. Brooks S, Bownes P, Lowe G, Bryant L, Hoskin PJ: Cervical brachytherapy utilizing ring applicator: comparison of standard and conformal loading. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):934-9
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Afterloading high-dose-rate brachytherapy (HDR) treatment of cervical cancer with cross-sectional imaging and three-dimensional (3D) reconstruction offers opportunities for individualized conformal treatment planning rather than fixed point-A dosimetry.
  • METHODS AND MATERIALS: Between June 2003 and September 2004, 15 patients with FIGO Stage 1B-4A cervical carcinoma, median age 56 years, were treated with radical external-beam radiotherapy to pelvis, including paraortic nodes if positive on staging investigations.
  • Fourteen patients received concurrent cisplatin chemotherapy.
  • Clinical target volume (CTV) and organs at risk (OAR)--rectum, bladder, and small bowel--were outlined from postinsertion CT planning scans.
  • A standard plan was produced that delivered 6 Gy to point A, and a second plan delivered 6 Gy to PTV.
  • Constraints were defined for the OAR: bladder, 6 Gy; rectum, 5 Gy; and small bowel, 5 Gy.
  • RESULTS: Mean COIN values were 0.39 for conformal plans and 0.33 for standard plans (p = 0.001); mean D95 values were 4.79 Gy and 4.50 Gy, respectively.
  • CONCLUSION: The majority of patients achieved a plan closer to ideal for coverage of PTV, with minimization of radiation received by normal tissues for conformal loading measured by COIN compared with fixed point-A prescription that used the cervical ring applicator.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestine, Small / radiation effects. Middle Aged. Radiation Injuries / prevention & control. Rectum / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199322.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Culy C: Bevacizumab: antiangiogenic cancer therapy. Drugs Today (Barc); 2005 Jan;41(1):23-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab: antiangiogenic cancer therapy.
  • In addition, bevacizumab has shown antiangiogenic and antitumor activity in several cancer types, recently gaining approval from the FDA for use in combination with fluorouracil-based chemotherapy as a first-line treatment for metastatic cancer of the colon or rectum.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Prous Science. All rights reserved.
  • (PMID = 15753967.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 64
  •  go-up   go-down


19. Marrs J, Zubal BA: Oncology nursing in a new era: optimizing treatment with bevacizumab. Clin J Oncol Nurs; 2009 Oct;13(5):564-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncology nursing in a new era: optimizing treatment with bevacizumab.
  • Overexpression of vascular endothelial growth factor (VEGF) by tumor cells promotes angiogenesis, which correlates with progressive tumor growth and poor outcomes in many types of cancer.
  • Bevacizumab inhibits VEGF to promote regression of tumor vessels by limiting blood supply and tumor growth, enhancing delivery of chemotherapy, and inhibiting formation of new vessels.
  • Combined with chemotherapy, bevacizumab prolongs progression-free and overall survival over chemotherapy alone in patients with metastatic carcinoma of the colon and rectum; unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC); and metastatic HER2-negative breast cancers (mBC).
  • To optimize patient outcomes, nurses should understand bevacizumab's role in cancer therapy, recognize symptoms of toxicity, and manage its side effects.
  • This article describes the rationale for bevacizumab in the treatment of metastatic colorectal cancer, NSCLC, and mBC and discusses patient selection, treatment duration, and side-effect management to support the role of oncology nurses in caring for, educating, and enhancing treatment adherence among patients with cancer receiving bevacizumab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Oncology Nursing

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793713.001).
  • [ISSN] 1538-067X
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


20. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only small numbers of bona fide examples exist in the world literature; cases arising primarily at extranodal sites are not well described and often seem to go unrecognized.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Salom EM, Penalver M: Recurrent vulvar cancer. Curr Treat Options Oncol; 2002 Apr;3(2):143-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent vulvar cancer occurs in an average of 24% of cases after primary treatment after surgery with or without radiation.
  • The relatively few primary vulvar cancers, combined with the low proportion of recurrences, has made it difficult to perform randomized studies to document the most appropriate therapeutic modalities.
  • Most reports are small retrospective studies and anecdotal reviews that have emphasized the importance of surgery and have led to new approaches with respect to chemoradiation.
  • Traditionally, the most accepted treatment of vulvar cancer has been and continues to be surgery.
  • Recently, radiation and chemotherapy have been combined with very encouraging results.
  • The therapeutic modality used depends on the location and extent of the recurrence.
  • With a central pelvic recurrence with antecedent radiotherapy involving the urethra, upper vagina, and rectum, total pelvic exenteration is indicated in a select group of patients with curative intent.
  • We recommend that inguinal recurrences without prior radiation therapy undergo excision followed by radiotherapy with chemosensitization.
  • With pelvic recurrences, we recommended chemoradiation as the treatment modality.
  • In the subset of patients with distant metastasis, chemotherapy may be offered; however, few studies have been performed to advocate any single combination.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1990 Sep;163(3):1007-15 [2403127.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1943-9 [6478428.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):91-8 [10411801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1193-7 [10725631.001]
  • [Cites] Am J Obstet Gynecol. 1990 May;162(5):1278-82 [2339729.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):202-5 [7622106.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):263-7 [2504651.001]
  • [Cites] Acta Radiol Oncol. 1984;23(5):345-8 [6095605.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1383-9 [1442996.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):189-95 [8428690.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(4):318-22 [8344328.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):343-8 [9731836.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1001-5 [2342725.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2835-8 [1451064.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Gynecol Oncol. 1986 Feb;23(2):192-8 [3943761.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):321-7 [8641609.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):51-6 [7557615.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):309-14 [2227541.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26 [3549645.001]
  • [Cites] Am J Obstet Gynecol. 1982 Jun 1;143(3):340-51 [7081350.001]
  • [Cites] Gynecol Oncol. 1991 Sep;42(3):197-201 [1955180.001]
  • [Cites] Am J Clin Oncol. 1987 Apr;10(2):171-81 [3565317.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):14-20 [1427394.001]
  • (PMID = 12057077.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 27
  •  go-up   go-down


22. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med; 2001 May-Jun;7(3):57-66, 68-72, 74-6 passim
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
  • CONTEXT: In anthroposophical medicine, total extracts of Viscum album (mistletoe) have been developed to treat cancer patients.
  • Although Iscador is regarded as a complementary cancer therapy, it is the most commonly used oncological drug in Germany.
  • OBJECTIVE: To determine whether Iscador treatment prolongs survival time of patients with carcinoma of the colon, rectum, or stomach; breast carcinoma with or without axillary or remote metastases; or small cell or non-small-cell bronchogenic carcinoma; and to explore synergies between Iscador treatment and psychosomatic self-regulation.
  • MAIN OUTCOME MEASURE: Survival time.
  • RESULTS: In the nonrandomized matched-pair study, survival time of patients treated with Iscador was longer for all types of cancer studied.
  • In the pool of 396 matched pairs, mean survival time in the Iscador groups (4.23 years) was roughly 40% longer than in the control groups (3.05 years; P < .001).
  • Synergies between Iscador treatment and self-regulation manifested in a longer survival advantage for Iscador patients with good self-regulation (56% relative to control group; P = .03) than for patients with poor self-regulation.
  • CONCLUSION: Iscador treatment can achieve a clinically relevant prolongation of survival time of cancer patients and appears to stimulate self-regulation.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Mistletoe. Neoplasms / drug therapy. Neoplasms / mortality. Phytotherapy. Plant Extracts / therapeutic use. Plant Proteins. Plants, Medicinal

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11347286.001).
  • [ISSN] 1078-6791
  • [Journal-full-title] Alternative therapies in health and medicine
  • [ISO-abbreviation] Altern Ther Health Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Plant Proteins; 0 / viscum album peptide
  •  go-up   go-down


23. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • Ileal ET's, even if small, are malignant, frequently multiple, and complicated in 30-50% of cases by bowel obstruction, mesenteric invasion, or bleeding.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • The lesions are frequently small, multiple, and widespread and recurrence is frequent after excision.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


24. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D: Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res; 2010 Apr 1;70(7):2870-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment-related DNA hypermethylation may play a role in creating drug-resistant phenotypes by inactivating genes that are required for cytotoxicity.
  • We applied a pharmacologic unmasking approach to detect hypermethylated genes whose inactivation contributes to cisplatin resistance.
  • Using three pairs of isogeneic, cisplatin-sensitive, and cisplatin-resistant cell lines derived from two parental cell lines (KB-3-1 and SCC25), we identified several hundred genes that were downregulated in each resistant cell line and reactivated by the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
  • Among them, 30 genes were common to two or more cell lines and/or reported to be downregulated in previous studies.
  • Bisulfite sequencing confirmed that 14 genes were hypermethylated in resistant cell lines but not in the sensitive parental cell lines.
  • Six of 14 genes (SAT, C8orf4, LAMB3, TUBB, G0S2, and MCAM) were cisplatin inducible in sensitive but not in resistant cell lines.
  • Small interfering RNA knockdown of two genes, SAT and S100P, increased cell viability with cisplatin treatment in sensitive parental cell lines.
  • S100P knockdown significantly decreased the S-phase fraction of parental sensitive cell lines and slowed cell proliferation, which was associated with decreased sensitivity to cisplatin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 2000;59 Suppl 4:9-17; discussion 37-8 [10864226.001]
  • [Cites] Anticancer Drugs. 2007 Jul;18(6):633-9 [17762391.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Nat Genet. 2001 May;28(1):29-35 [11326271.001]
  • [Cites] Cell. 2002 Apr 5;109(1):113-24 [11955451.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):485-95 [12498717.001]
  • [Cites] Nat Med. 2003 May;9(5):568-74 [12692539.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5909-16 [14522917.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7262-4 [14576836.001]
  • [Cites] Breast Cancer Res Treat. 2003 Dec;82(3):199-206 [14703067.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5059-65 [14617629.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1531-8 [14716296.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4420-6 [15240532.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):270-6 [15199393.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):813-22 [15252142.001]
  • [Cites] Ann N Y Acad Sci. 1993 Nov 30;698:193-203 [8279757.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1029-32 [7734295.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Prostate. 1996 Dec;29(6):350-5 [8977631.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4059-69 [9199341.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):33-40 [9724091.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):131-41 [10388527.001]
  • [Cites] Phys Med Biol. 2005 Jan 7;50(1):93-102 [15715425.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1396-402 [15608674.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):302-9 [16052217.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1677-86 [15905201.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1199-207 [16424059.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):128-37 [17237273.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):101-37 [17276603.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1089-98 [17363502.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):711-23 [17021820.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1230-40 [17587138.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(13):1935-43 [17689067.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1529-38 [17761710.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • (PMID = 20215521.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA096784-01; United States / NCI NIH HHS / CA / CA084986-01; United States / NIDCR NIH HHS / DE / R37 DE012588-06A1; United States / NCI NIH HHS / CA / P50 CA096784; United States / NIDCR NIH HHS / DE / P50 DE019032; United States / NIDCR NIH HHS / DE / DE012588-06A1; United States / NIDCR NIH HHS / DE / R37 DE012588; United States / NCI NIH HHS / CA / U01 CA084986-01; United States / NCI NIH HHS / CA / CA096784-01; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / S100P protein, human; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS173396; NLM/ PMC2849007
  •  go-up   go-down


25. O'Connell JB, Maggard MA, Ko CY: Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol; 2004 Nov;11(11):962-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies report underuse of radiation and chemotherapy in the elderly, yet few have examined the rates of use (or underuse) of surgery.
  • METHODS: By using the Surveillance, Epidemiology, and End RESULTS database (1988-1997), patients (> or =40 years) were identified with localized adenocarcinoma of the breast, esophagus, stomach, pancreas, colon, or rectum; non-small-cell lung carcinoma; and sarcoma (n = 200,360).
  • CONCLUSIONS: Although CDS for localized disease is being performed regularly in the elderly for some cancers (e.g. breast, colon, and rectum), this analysis shows that elderly patients are not receiving surgery for many potentially curable cancers.

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2004 Nov;11(11):951-2 [15525821.001]
  • (PMID = 15525824.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Zlobec I, Lugli A: Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget; 2010 Nov;1(7):651-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In colorectal cancer, tumor cells having undergone EMT are histologically represented by the presence of tumor buds defined as single cells or small clusters of de-differentiated tumor cells at the invasive front.
  • Strong, consistent evidence shows that tumor budding is a predictor of lymph node metastasis, distant metastatic disease, local recurrence, worse overall and disease-free survival time and an independent prognostic factor.
  • The aim of this review is to summarize the evidence supporting the implementation of tumor budding into diagnostic pathology and patient management and additionally to illustrate its worthiness as a potential therapeutic target.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma / pathology. Colorectal Neoplasms / pathology. Epithelial-Mesenchymal Transition / physiology. Molecular Targeted Therapy / methods. Pseudopodia / drug effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2006;202(9):663-70 [16860493.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1422-30 [16767517.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9543-56 [17018611.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1059-64 [16940750.001]
  • [Cites] Histopathology. 2007 Jan;50(1):151-62 [17204028.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):624-31 [17223543.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):221-32 [17361206.001]
  • [Cites] J Pathol. 2007 Jul;212(3):260-8 [17516584.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):863-8 [17216219.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):29-39 [17587805.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1597-602 [15937624.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):48-56 [17631130.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):386-95 [17600130.001]
  • [Cites] J Clin Pathol. 2007 Aug;60(8):912-5 [16997919.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1370-6 [17661146.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6871s-6s [18006792.001]
  • [Cites] Colorectal Dis. 2008 Jan;10(1):41-7 [18078460.001]
  • [Cites] Dis Colon Rectum. 2008 May;51(5):568-72 [18286339.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1773-8 [18630458.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1831-6 [18630467.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4C):2417-20 [18751428.001]
  • [Cites] Int J Oncol. 2009 Jan;34(1):53-60 [19082477.001]
  • [Cites] J Pathol. 2009 Jan;217(2):307-17 [19031475.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):134-41 [18971777.001]
  • [Cites] Virchows Arch. 2009 May;454(5):541-8 [19360438.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1417-9 [19487817.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] Jpn J Clin Oncol. 2002 Oct;32(10):412-6 [12451038.001]
  • [Cites] Clin Colorectal Cancer. 2002 Nov;2(3):149-60 [12482331.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):69-73 [12499439.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 [12511867.001]
  • [Cites] Dig Dis Sci. 2003 Feb;48(2):272-8 [12643602.001]
  • [Cites] Am J Clin Pathol. 2009 Aug;132(2):202-10; quiz 307 [19605814.001]
  • [Cites] J Transl Med. 2009;7:56 [19583834.001]
  • [Cites] Nat Protoc. 2009;4(11):1591-613 [19834475.001]
  • [Cites] Histopathology. 2009 Nov;55(5):564-75 [19912362.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):70-8 [19740518.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5898-906 [20014453.001]
  • [Cites] World J Gastroenterol. 2010 Feb 14;16(6):732-9 [20135722.001]
  • [Cites] Dis Colon Rectum. 2010 Mar;53(3):301-7 [20173477.001]
  • [Cites] Gastroenterology. 2010 Apr;138(4):1406-17 [20026115.001]
  • [Cites] Carcinogenesis. 2010 Apr;31(4):597-606 [20118200.001]
  • [Cites] J Cell Sci. 2010 Apr 15;123(Pt 8):1295-305 [20332115.001]
  • [Cites] PLoS One. 2010;5(4):e10221 [20421926.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Jun;42(6):911-20 [20109579.001]
  • [Cites] Oncogene. 2010 Jun 17;29(24):3490-500 [20418909.001]
  • [Cites] Am J Clin Pathol. 2010 Aug;134(2):312-22 [20660337.001]
  • [Cites] Mod Pathol. 2010 Aug;23(8):1068-72 [20473277.001]
  • [Cites] Histopathology. 2010 Aug;57(2):233-43 [20716165.001]
  • [Cites] J Surg Oncol. 2010 Sep 1;102(3):235-41 [20740581.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jul;21(7):1115-21 [16824062.001]
  • [Cites] Int J Cancer. 2011 Mar 1;128(5):1080-94 [20473920.001]
  • [Cites] Int J Cancer. 2011 May 1;128(9):2031-7 [20635387.001]
  • [Cites] Histopathology. 2011 Sep;59(3):482-95 [22034888.001]
  • [Cites] World J Gastroenterol. 2010 Oct 14;16(38):4823-31 [20939111.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1317-21 [11355941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61 [11526241.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1074-81 [11676858.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2539-46 [11745187.001]
  • [Cites] Histopathology. 2002 Feb;40(2):127-32 [11952856.001]
  • [Cites] J Surg Oncol. 2003 May;83(1):42-7 [12722096.001]
  • [Cites] Dig Dis Sci. 2003 Jul;48(7):1262-7 [12870781.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1054-9 [12907899.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1009-13 [12963980.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):327-33 [14991634.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):385-94 [15300569.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):832-9 [15492565.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):585-9 [3722412.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):539-43 [2912530.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • [Cites] Dis Colon Rectum. 1995 Jan;38(1):19-26 [7813339.001]
  • [Cites] J Pathol. 1995 Jun;176(2):151-9 [7636625.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1329-40 [9178893.001]
  • [Cites] Hum Pathol. 1998 Jun;29(6):627-35 [9635685.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Oct;14(10):1004-9 [10530497.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1193-5 [15754403.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):893-8 [15821121.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv74-79 [15923435.001]
  • [Cites] Cells Tissues Organs. 2005;179(1-2):56-65 [15942193.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1182-92 [15793641.001]
  • [Cites] Histopathology. 2005 Jul;47(1):17-24 [15982319.001]
  • [Cites] Histopathology. 2005 Jul;47(1):25-31 [15982320.001]
  • [Cites] J Surg Oncol. 2005 Oct 1;92(1):59-63 [16180229.001]
  • [Cites] Hepatogastroenterology. 2005 Sep-Oct;52(65):1432-5 [16201089.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1589-94 [16619576.001]
  • [Cites] Hum Pathol. 2006 May;37(5):578-85 [16647956.001]
  • [Cites] Eur J Cancer. 2006 May;42(7):964-71 [16563744.001]
  • [Cites] Hum Pathol. 2006 Aug;37(8):1022-31 [16867865.001]
  • (PMID = 21317460.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3248128
  •  go-up   go-down


27. Scott LJ: Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs; 2007;67(12):1793-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab: in first-line treatment of metastatic breast cancer.
  • Bevacizumab, a recombinant humanised monoclonal antibody against vascular endothelial growth factor, is approved in Europe as first-line therapy for metastatic breast cancer (mBC) and metastatic carcinoma of the colon or rectum (mCRC); the European Medicines Agency gave a positive opinion recommending its use in non-small-cell lung cancer (NSCLC) and is also considering other indications.
  • In the US, it is licensed for use for mCRC and NSCLC, with its use as first-line treatment in mBC under review by the US FDA.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):598-609 [15487459.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3(6):421-2 [12636887.001]
  • [Cites] Angiogenesis. 2004;7(4):335-45 [15886877.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):289-95 [12607595.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):851-6 [11157039.001]
  • [Cites] Pharm Res. 2002 Nov;19(11):1753-6 [12458683.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5 Suppl 10):6-13 [15490369.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):292-302 [15120666.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12 ):1979-86 [12799646.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):843-50 [11157038.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • (PMID = 17683175.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 26
  •  go-up   go-down


28. Yamashita H, Nakagawa K, Asari T, Murakami N, Igaki H, Ohtomo K: Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol; 2008 Jun;87(3):412-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct disease with specific clinical and pathologic features that may affect diverse organs.
  • We analyzed our recent experience with Stage I/II MALT lymphoma presenting in the stomach and other organs to assess the outcome following radiation therapy (RT) alone.
  • Presenting sites included stomach, 11; orbital adnexa, 21; thyroid, 1; other head and neck, 3; small bowel, 3; skin, 1; and rectum, 1.
  • Mean follow-up time was 32.0 months (range, 2.1-162 months).
  • Only one patient died from bile duct carcinoma at 22 months from the start of irradiation for conjunctiva MALT lymphoma without recurrence of lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Male. Middle Aged. Radiation Injuries / pathology. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423914.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


29. Yegüez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • We included adult patients, with ELISA and Western blot test positive for HIV, and primary malignant tumors located in the colon or rectum.
  • Twelve patients (9 males and 3 females), mean age 41 years, were identified with the following neoplasm: 6 adenocarcinomas (ACA), 5 non-Hodgkin lymphomas (NHL), and 1 small-cell carcinoma.
  • Intravenous drug abuse was the main risk factor for HIV.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.






Advertisement